Cyclophosphamide: new approaches for systemic lupus erythematosus.
about
Predictors of intestinal pseudo-obstruction in systemic lupus erythematosus complicated by digestive manifestations: data from a Southern China lupus cohort.Failure of oral atorvastatin to modulate a murine model of systemic lupus erythematosus.Mycophenolate mofetil versus cyclophosphamide for induction treatment of lupus nephritisIgG immunoadsorption reduces systemic lupus erythematosus activity and proteinuria: a long term observational study.Efficacy of rituximab (anti-CD20) for refractory systemic lupus erythematosus involving the central nervous system.The effect of calcineurin inhibitors in the induction and maintenance treatment of lupus nephritis: a systematic review and meta-analysis.Metabolism and transport of oxazaphosphorines and the clinical implications.Nanogel-based delivery of mycophenolic acid ameliorates systemic lupus erythematosus in mice.Genetic markers in CYP2C19 and CYP2B6 for prediction of cyclophosphamide's 4-hydroxylation, efficacy and side effects in Chinese patients with systemic lupus erythematosus.Infections and systemic lupus erythematosusInduction and maintenance therapy for lupus nephritis: a systematic review and meta-analysis.Efficacy and safety of tacrolimus therapy for lupus nephritis: a systematic review of clinical trials.Systemic lupus erythematosus: a genetic review for advanced practice nurses.Efficacy and safety of mycophenolate mofetil versus cyclophosphamide for induction therapy of lupus nephritis: a meta-analysis of randomized controlled trials.Systemic lupus erythematosus: a therapeutic challenge for the XXI century.Treatment of severe lupus nephritis: the new horizon.Relative efficacy and safety of tacrolimus, mycophenolate mofetil, and cyclophosphamide as induction therapy for lupus nephritis: a Bayesian network meta-analysis of randomized controlled trials.Mycophenolate mofetil as induction and maintenance therapy for lupus nephritis: rationale and protocol for the randomized, controlled Aspreva Lupus Management Study (ALMS).Concentration-controlled treatment of lupus nephritis with mycophenolate mofetil.Mycophenolate mofetil is effective in reducing disease flares in systemic lupus erythematosus patients: a retrospective study.Health-related quality of life in patients with systemic lupus erythematosus and proliferative lupus nephritis.Predictive factors of clinical outcome in patients with diffuse proliferative lupus nephritis treated early by intravenous methylprednisolone pulse therapy.Efficacy and safety of rituximab in comparison with common induction therapies in pediatric active lupus nephritis.
P2860
Q30997109-A89EDCAA-8214-4AA8-B9A4-484AF2C69A0AQ34084153-69BB050D-803D-45DB-886A-D3EA8B26AB42Q34975939-87BE48D9-B558-48C8-8053-980333767990Q35555714-8AF0CC14-7EF1-4075-A729-80EA9436D28CQ35760171-ABADB435-1599-4FD2-A85C-FD97D1DCE057Q35897121-083D366C-A21A-4571-A80C-F66B843E1277Q36360811-61BAB728-8908-45BE-8679-A50C1A42AC0BQ36733468-34405BF2-F0F7-4F16-9785-840809F3C7C2Q36802054-FF1FA1CC-4AB5-40B3-A48A-51E763D8EE74Q36916866-81641BCC-6EF9-4466-8F14-A49D8F20D2E7Q37671987-B73F1444-4AF3-4428-AB20-A87F5C1D5D6FQ37850608-DA443553-D8DD-4521-AD62-879DD563B2FCQ37965222-9B47B817-CD61-4A52-AB09-7203090FABF5Q38028010-FF3EE60B-6F26-4413-8FAF-EE91A069E10BQ38191835-2BC8A4EB-A5B1-4275-A43B-864B93C9AF14Q38271125-7B403227-82F9-4D44-AD0A-5A036ECA948EQ41114245-E29FB80A-8E21-4B26-B7AD-C9B147463C3DQ42638034-B4275BD6-34B2-4D88-9542-8C15182148C1Q45353017-E9E24158-D5BB-4079-8618-754DBBDE9496Q46076332-A6DA79F8-5315-4149-BAF6-C8ABFB1231FFQ48631387-2EC7B0B3-01A3-44EB-BF89-079A5AA4A5D4Q50702177-392455F7-14DE-485F-88A7-30A44446A9F5Q51140299-1C5E670E-F412-473C-B1BE-831C5230B8A0
P2860
Cyclophosphamide: new approaches for systemic lupus erythematosus.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
2004年论文
@zh
2004年论文
@zh-cn
name
Cyclophosphamide: new approaches for systemic lupus erythematosus.
@ast
Cyclophosphamide: new approaches for systemic lupus erythematosus.
@en
type
label
Cyclophosphamide: new approaches for systemic lupus erythematosus.
@ast
Cyclophosphamide: new approaches for systemic lupus erythematosus.
@en
prefLabel
Cyclophosphamide: new approaches for systemic lupus erythematosus.
@ast
Cyclophosphamide: new approaches for systemic lupus erythematosus.
@en
P2860
P1433
P1476
Cyclophosphamide: new approaches for systemic lupus erythematosus.
@en
P2860
P304
P356
10.1191/0961203303LU1028OA
P577
2004-01-01T00:00:00Z